[1] WIN T T,KAMALUDIN Z,HUSIN A.Primary mediastinal large B-cell lymphoma and its mimickers:a rare case report with literature review[J]. Malays J Pathol,2016,38(2):153-157.
[2] ZINZANI P L,RIBRAG V,MOSKOWITZ C H,et al.Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma[J]. Blood,2017,130(3):267-270.
[3] TOMASSETTI S,CHEN R,DANDAPANI S.The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma[J].Ther Adv Hematol,2019,10:2040620719841591.
[4] MARTELLI M,ROCCO A D,RUSSO E,et al.Primary mediastinal lymphoma:diagnosis and treatment options[J]. Expert Rev Hematol,2015,8(2):173-186.
[5] VAN ROOSBROECK K,FERREIRO J F,TOUSSEYN T,et al.Genomic alterations of the JAK2 and PDL loci occur in a broad spectrum of lymphoid malignancies[J].Genes Chromosomes Cancer,2016,55(5):428-441.
[6] SHI M,ROEMER M G M,CHAPUY B,et al. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain[J]. Am J Surg Pathol,2014,38(12):1715-1723.
[7] MARTELLI M,FERRERI A,DI ROCCO A,et al.Primary mediastinal large B-cell lymphoma[J]. Crit Rev Oncol,2017,113:318-327.
[8] LEES C,KEANE C,GANDHI M K,et al.Biology and therapy of primary mediastinal B-cell lymphoma:current status and future directions[J].Br J Haematol,2019,185(1):25-41.
[9] STEIDL C,GASCOYNE R D.The molecular pathogenesis of primary mediastinal large B-cell lymphoma[J].Blood,2011,118(10):2659-2669.
[10] BAI B,HUANG H Q,CAI Q Q,et al.Promising long-term outcome of gemcitabine,vinorelbine,liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma[J]. Med Oncol,2013,30(1):1-7.
[11] MEI Q,ZHANG W Y,LIU Y,et al.Camrelizumab plus gemcitabine,vinorelbine,and pegylated liposomal doxorubicin in relapsed/refractory primary mediastinal B-cell lymphoma:a single-arm,open-label,phase II trial[J]. Clin Cancer Res,2020,26(17):4521-4530.
[12] DUNLEAVY K,PITTALUGA S,MAEDA L S,et al.Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma[J].N Engl J Med,2013,368(15):1408-1416.
[13] CAZALS-HATEM D,LEPAGE E,BRICE P,et al.Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas,a GELA (“Groupe d'Etude des Lymphomes de l'Adulte”) study[J]. Am J Surg Pathol,1996,20(7):877-888.
[14] BISHOP P C,WILSON W H,PEARSON D,et al.CNS involvement in primary mediastinal large B-cell lymphoma[J]. J Clin Oncol,1999,17(8):2479-2485.
[15] SHEMMARI S A,SANKARANARAYANAN S P,KRISHNAN Y.Primary mediastinal large B-cell lymphoma:clinical features,prognostic factors and survival with RCHOP in Arab patients in the PET scan era[J]. Lung India,2014,31(3):228-231.
[16] POIRÉ X,VAN BESIEN K.Autologous transplant for primary mediastinal B-cell lymphoma[J]. Expert Rev Hematol,2009,2(1):31-36.
[17] FENSKE T S,AHN K W,GRAFF T M,et al.Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation[J]. Br J Haematol,2016,174(2):235-248.
[18] HERRERA A F,CHEN L,KHAJAVIAN S,et al.Allogeneic stem cell transplantation provides durable remission in patients with primary mediastinal large B cell lymphoma[J]. Biol Blood Marrow Transplant,2019,25(12):2383-2387.
[19] WANG J J,LIU X L,MA F,et al.Role of radiotherapy in the treatment of primary mediastinal large B-cell lymphoma[J]. Oncol Lett,2015,10(5):2925-2930.
[20] COLEMAN M,LAMMERS P E,CICERI F,et al.Role of rituximab and rituximab biosimilars in diffuse large B-cell lymphoma[J]. Clin Lymphoma Myeloma Leuk,2016,16(4):175-181.
[21] MONK B J,FACCIABENE A,BRADY W E,et al.Integrative development of a TLR8 agonist for ovarian cancer chemoimmunotherapy[J]. Clin Cancer Res,2017,23(8):1955-1966.
[22] XU-MONETTE Z Y,ZHOU J F,YOUNG K H. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas[J]. Blood,2018,131(1):68-83.
[23] HUANG G,HUANG J,ZHANG Z L,et al.Nivolumab plus gemcitabine,dexamethasone,and cisplatin chemotherapy induce durable complete remission in relapsed/refractory primary mediastinal B-cell lymphoma:a case report and literature review[J]. J Int Med Res,2020,48(8):300060520945075.
[24] ANSELL S M,LESOKHIN A M,BORRELLO I,et al.PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma[J]. N Engl J Med,2015,372(4):311-319.
[25] SHI Y K,SU H,SONG Y P,et al.Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1):a multicentre,single-arm,phase 2 trial[J]. Lancet Haematol,2019,6(1):e12-e19.
[26] ARMAND P,RODIG S,MELNICHENKO V,et al.Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma[J]. J Clin Oncol,2019,37(34):3291-3299.
[27] SHI Y K,SU H,SONG Y P,et al.Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical Hodgkin lymphoma treated with sintilimab[J]. EBioMedicine,2020,54:102731.
[28] SHI Y,LI Q Y,ZHANG W J,et al.Sintilimab as salvage treatment in an HIV patient with relapsed/refractory Hodgkin:a case report[J]. Ann Palliat Med,2020,9(4):2414-2419. |
